Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Rang in Aktien
#3628
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Aktienkurs
$3.71
Marktkapitalisierung
$4.69B
Veränderung (1 Tag)
2.44%
Veränderung (1 Jahr)
-51.92%
Land
CN
Handel Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Kategorie
Healthcare
Gewinn für Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Gewinn im Jun 2026 TTM: $-68.50M
Laut den aktuellen Finanzberichten von Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. betragen die aktuellen Gewinne des Unternehmens $-68.50M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $196.85M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $809.33M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. von 2013 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-68.50M | -840.89% |
| 2024 | $9.25M | -95.30% |
| 2023 | $196.85M | -75.68% |
| 2022 | $809.33M | 121.33% |
| 2021 | $365.67M | 212.48% |
| 2020 | $117.02M | 275.84% |
| 2019 | $31.14M | -26.22% |
| 2018 | $42.20M | 53.78% |
| 2017 | $27.44M | 24.77% |
| 2016 | $21.99M | 8.94% |
| 2015 | $20.19M | -6.87% |
| 2014 | $21.68M | 27.42% |
| 2013 | $17.01M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -7,801.05% |
US
|
|
| $-3.09B | 4,406.84% |
US
|
|
| $-4.02B | 5,763.42% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,947.84% |
NL
|
